Radiation plus immunotherapy shows promise in rare lung cancer trial
NCT ID NCT02959463
First seen Nov 14, 2025 · Last updated Jun 13, 2026 · Updated 29 times
Summary
This early-stage trial tested whether giving the immunotherapy drug pembrolizumab after radiation therapy is safe for people with pleural mesothelioma, a rare cancer of the lung lining. Twenty-five participants received the combination to check for severe side effects. The goal was to find the best way to deliver this treatment and see if it helps control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MALIGNANT MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.